Fulcrum Therapeutics (NASDAQ:FULC – Get Free Report) and Laboratorios Farmaceuticos Rovi (OTCMKTS:LABFF – Get Free Report) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, profitability and earnings.
Insider & Institutional Ownership
89.8% of Fulcrum Therapeutics shares are held by institutional investors. 2.5% of Fulcrum Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Earnings and Valuation
This table compares Fulcrum Therapeutics and Laboratorios Farmaceuticos Rovi’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Fulcrum Therapeutics||$6.34 million||43.78||-$109.87 million||($1.80)||-2.49|
|Laboratorios Farmaceuticos Rovi||N/A||N/A||N/A||N/A||N/A|
This table compares Fulcrum Therapeutics and Laboratorios Farmaceuticos Rovi’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Laboratorios Farmaceuticos Rovi||N/A||N/A||N/A|
This is a summary of recent recommendations and price targets for Fulcrum Therapeutics and Laboratorios Farmaceuticos Rovi, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Laboratorios Farmaceuticos Rovi||0||0||0||0||N/A|
Fulcrum Therapeutics currently has a consensus target price of $11.25, suggesting a potential upside of 150.56%. Given Fulcrum Therapeutics’ higher possible upside, equities analysts plainly believe Fulcrum Therapeutics is more favorable than Laboratorios Farmaceuticos Rovi.
Fulcrum Therapeutics beats Laboratorios Farmaceuticos Rovi on 5 of the 8 factors compared between the two stocks.
About Fulcrum Therapeutics
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
About Laboratorios Farmaceuticos Rovi
Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, production, and sale of pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company distributes other products that are licensed from other laboratories. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It provides non-prescription pharmaceutical products; and contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, hard capsules, and sachets. The company was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.
Receive News & Ratings for Fulcrum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulcrum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.